Skip to content

Locally advanced prostate cancer (cT3): can it be operated on?

When the tumor has grown beyond the prostate, whether surgery is still an option and what the studies show.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 19, 2026
Book a consultation
Drawing of the pelvis from the side, with the bladder, prostate and rectum, and a tumor at the back of the prostate that grows through the capsule and up into the seminal vesicle, without reaching the rectum
On this page

Quick answer

Locally advanced prostate cancer has grown beyond the prostate capsule (cT3 or cT4) or has suspicious lymph nodes, without distant metastases.1 It can still be operated on in selected cases: the European guideline recommends offering radical prostatectomy to these patients, without suspicious lymph nodes, as part of treatment that may include radiotherapy afterwards. The other option is radiotherapy with at least 2 years of hormone therapy.2 I operate on T3 cancer, including when there are suspicious lymph nodes (cN1), always robotically and with extended lymph node dissection when the nodes are removed.

What locally advanced cancer is

The clinical stage (the letter "c") comes from the rectal examination. The European guideline uses the TNM classification:1

StageWhat it means
cT3aThe tumor extends through the prostate capsule, on one or both sides
cT3bThe tumor reaches the seminal vesicles
cT4The tumor is fixed or invades nearby structures other than the seminal vesicles, such as the sphincter, rectum, bladder, pelvic floor muscles or pelvic wall
cN1Suspicious lymph nodes in the pelvis on imaging

In the 2026 European guideline risk table, any cT3, cT4 or cN1 counts as locally advanced, with any ISUP grade group and any PSA. A tumor that involves both sides of the prostate without extending through the capsule (cT2c) no longer counts as high risk.1 The risk group calculator shows which group your case falls into, and the high-risk page explains the neighboring group.

The rectal exam is not always right

The rectal exam tends to overestimate the tumor. In three surgical series of cT3 cancer, 23.5% to 27% of tumors were in fact confined to the prostate (pT2) when the specimen was examined.3,4,5 That is why prostate MRI and PSMA PET weigh heavily in planning: they show whether the tumor reaches the seminal vesicles, the sphincter and the lymph nodes.

The European guideline recommendations for locally advanced cancer were based on conventional imaging: CT or MRI with a bone scan.2

Can it still be operated on?

Many men with locally advanced cancer are told that surgery is no longer possible. The European guideline recommends offering radical prostatectomy to selected patients without suspicious lymph nodes, as part of combined treatment (weak recommendation).2 Surgery is an option when the tumor is not fixed to the pelvic wall and has not invaded the urethral sphincter.2

The studies of surgery for cT3 cancer are series from experienced centers, without randomization between treatments:

SourcePatientsResult
European guideline, 2026Case series of cT3Over 60% free of cancer death at 15 years and over 75% alive at 10 years. In cT3b and cT4, over 87% free of cancer death at 10 years2
Mitchell, 2012843 men operated on for cT381% free of cancer death at 20 years; 26% were pT2 in the specimen3
Ward, 2005Men operated on for cT3, compared with cT295%, 90% and 79% free of cancer death at 5, 10 and 15 years4
Hsu, 2007200 men with one-sided cT3a98.7% and 91.6% free of cancer death at 5 and 10 years5

In the 20-year series, most men needed more than one treatment, but many were treated with surgery alone.3 I operate on T3 cancer, and I also operate when there are suspicious lymph nodes (cN1), with extended lymph node dissection. Each case is selected as the guideline describes, together with you, looking at your scans.

Surgery or radiotherapy

For locally advanced cancer, the European guideline recommends:2

SituationSurgeryRadiotherapy
No suspicious lymph nodes (cN0)Offer to selected patients, as part of combined treatment, with extended lymph node dissectionWith hormone therapy for at least 2 years; with two high-risk factors, also abiraterone for 2 years
Suspicious lymph nodes (cN1)The guideline's surgery recommendation is for cN0To the prostate and pelvis, with long-term hormone therapy and abiraterone for 2 years

The high-risk factors that lead to abiraterone are any two of these: a cT3 or cT4 tumor, Gleason 8 to 10, or PSA of 40 ng/mL or more.2,8 The guideline does not recommend focal or whole-gland treatments, such as HIFU or cryotherapy, in this setting.2

The strength of radiotherapy with hormone therapy comes from randomized trials. In SPCG-7, adding radiotherapy to hormone therapy reduced 10-year prostate cancer death from 23.9% to 11.9%.6 In the EORTC trial, adding 3 years of hormone therapy to radiotherapy reduced 10-year prostate cancer death from 30.4% to 10.3%.7

No study has compared surgery with radiotherapy head to head in locally advanced cancer. SPCG-15, in the Nordic countries, randomizes men between prostatectomy with extended lymph node dissection and radiotherapy with hormone therapy, with at least 10 years of follow-up.9 Cancer control results are not yet available.2 The page surgery or radiotherapy compares the effects of each on urine, erections and the bowel, and the radiotherapy and hormone therapy pages explain each treatment.

Surgery for cT3 cancer

In my practice, radical prostatectomy is always robotic. In locally advanced cancer, some points matter more:

  • Lymph nodes: the guideline recommends that, when the lymph nodes are removed, the dissection be extended.2 I decide on node removal with the Briganti nomograms, using the 7% cut-off of the 2019 nomogram, and when I remove the nodes, the dissection is always extended.12 When there are suspicious lymph nodes (cN1), I also operate, with extended dissection. The pelvic lymph node dissection page explains how it is done.
  • Suspicious node during surgery: the guideline advises completing the prostatectomy, without frozen section of the nodes.2
  • Erection nerves: high-risk disease does not rule out nerve sparing, but the nerve is usually removed on the side where the tumor is palpable or extends through the capsule on MRI.2 I spare the nerves whenever possible, side by side.
  • No hormone therapy beforehand: hormone therapy before prostatectomy is not recommended.2 I do not use hormone therapy while the patient waits for surgery, and when surgery is recommended, I advise operating as soon as possible.

Margins and what comes next

In the surgical series of cT3 cancer, a positive margin was linked to more PSA recurrence and a higher risk of prostate cancer death.3,5 The positive surgical margin page explains what that result on the pathology report means.

In my practice, with a positive margin and an undetectable PSA after surgery, I monitor PSA, as the European guideline advises. Two sets of studies published in 2020 compared radiotherapy right after surgery with salvage radiotherapy, given only when PSA rises:

  • RADICALS-RT: 1,396 men. At 5 years, 85% had no PSA rise with immediate radiotherapy and 88% with salvage, and immediate radiotherapy caused more urine leakage.10
  • ARTISTIC: the analysis of three trials, with 2,153 men, showed no advantage for immediate radiotherapy.11

The guideline still considers radiotherapy right after surgery when the report shows ISUP grade group 4 or 5 with tumor beyond the prostate (pT3) and negative lymph nodes (weak recommendation).2 The prostatectomy pathology report carries this information, and follow-up is covered in PSA after prostatectomy.

Continence and erections

In a 15-year series from the United States, complications and continence after surgery for cT3 cancer were similar to those in men operated on for cancer confined to the prostate.4 In my practice, I recommend Kegel exercises before and after surgery. The continence page explains recovery.

Erections depend a lot on how many nerves can be spared. When the tumor extends through the capsule on one side, the nerve on that side is usually removed with it, and the nerve on the other side may be spared.2 The page erections and ejaculation shows what to expect.

How I approach it

At the consultation, I review the biopsy, PSA, MRI and PSMA PET, explain the stage of the tumor and we talk about surgery and radiotherapy with hormone therapy, what each one offers and what may come afterwards.

I have a PhD from the University of São Paulo Medical School and Intuitive Surgical certification on the da Vinci Xi platform, and I have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I operate on T3 cancer, including with suspicious lymph nodes (cN1), always robotically, with extended lymph node dissection when the nodes are removed, and I spare the nerves whenever possible.

If you were told that surgery is no longer possible and want another assessment, a second opinion can be done entirely online, in English, with your test results sent in advance.

Send your case

If you have been diagnosed with locally advanced cancer and would like my opinion before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is locally advanced prostate cancer?

It is cancer that has grown beyond the prostate capsule on rectal examination (cT3 or cT4) or has suspicious lymph nodes on imaging, without distant metastases. In cT3a, the tumor extends through the capsule; in cT3b, it reaches the seminal vesicles; in cT4, it is fixed or invades nearby structures such as the rectum, bladder or pelvic wall.1

Can T3 prostate cancer be operated on?

Yes, in selected cases. The European guideline recommends offering radical prostatectomy to selected patients with locally advanced cancer and no suspicious lymph nodes, as part of treatment that may include radiotherapy or hormone therapy afterwards.2 Surgery is an option when the tumor is not fixed to the pelvic wall and has not invaded the urethral sphincter.2 I operate on T3 cancer, and each case is selected as the guideline describes.

For locally advanced cancer, is surgery or radiotherapy better?

No study has yet compared the two head to head. The European guideline accepts surgery in selected cases and recommends radiotherapy with hormone therapy for at least 2 years.2 A Scandinavian trial, SPCG-15, is randomizing men between the two options, and the results are not yet available.2,9

Do you operate when there are suspicious lymph nodes (cN1)?

Yes, with extended lymph node dissection. The European guideline's surgery recommendation is for men without suspicious lymph nodes (cN0); for cN1, it describes radiotherapy to the prostate and pelvis, with long-term hormone therapy and abiraterone.2 Each case is decided together with you, looking at your scans.

Will I need radiotherapy after surgery?

Possibly. In locally advanced cancer, surgery is often part of combined treatment, but many men are treated with surgery alone.3 When PSA starts to rise, early salvage radiotherapy has had the same results as radiotherapy given right after surgery, with fewer urinary side effects.10,11

Do I need hormone therapy before surgery?

No. The European guideline does not recommend hormone therapy before prostatectomy.2 In my practice, I do not use hormone therapy while the patient waits for surgery.

Can the erection nerves be spared in T3 cancer?

Sometimes, on one side. The European guideline says high-risk disease does not rule out nerve sparing, but the nerve is usually removed on the side where the tumor is palpable or extends through the capsule on MRI.2 I spare the nerves whenever possible, side by side.

Does surgery for T3 cancer cause more urine leakage?

In a 15-year series from the United States, complications and continence after surgery for cT3 cancer were similar to those for cancer confined to the prostate.4 In my practice, I recommend pelvic floor (Kegel) exercises before and after surgery.

Who operates on locally advanced prostate cancer in São Paulo?

I do. I am a urologist and robotic surgeon in São Paulo, Brazil, with a PhD from the University of São Paulo Medical School and more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. In my practice, radical prostatectomy is always robotic, and when I remove the lymph nodes, the dissection is always extended. The first consultation can be online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: classification and staging systems. European Association of Urology; 2026. EAU
  2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  3. Mitchell CR, Boorjian SA, Umbreit EC, et al. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110(11):1709-1713. PubMed
  4. Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751-756. PubMed
  5. Hsu CY, Joniau S, Oyen R, et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol. 2007;51(1):121-128. PubMed
  6. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301-308. PubMed
  7. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066-1073. PubMed
  8. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447-460. PubMed
  9. Stranne J, Brasso K, Brennhovd B, et al. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand J Urol. 2018;52(5-6):313-320. PubMed
  10. Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396(10260):1413-1421. PubMed
  11. Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422-1431. PubMed
  12. Gandaglia G, Ploussard G, Valerio M, et al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol. 2019;75(3):506-514. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides